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wealth of evidence attests that the organs of developing embryos, 
particularly the developing brain, are acutely sensitive to chemical 
perturbations. However, scientists know very little about how exposures 
to specific endogenous chemicals actually impact human development 
or children’s ability to learn. And there are almost no data on how the vast majority 
of the 84,000 chemicals currently listed in the Toxic Substances Control Act (TSCA) 
Inventory
1—including most of the 201 compounds known to be neurotoxic to adults 
and the 1,000 chemicals shown to be neurotoxic to animals
2—may affect developing 
infants. It is also unclear whether testing with animals always provides accurate 
insights into human developmental susceptibility.
A new line of research based on human stem cells is providing important insights into 
how chemicals may affect neonatal development. Stem cells are the master cells capable 
of producing some or all of the 200-plus different types of cells in the human body. In 
time, some researchers believe stem cells may enable scientists to amass far more data on 
how exposure to environmental chemicals affects human development, particularly the 
development of the brain. Now is a “critical time to be talking about stem cell research 
in the environmental health context,” says Tracey Woodruff, director of the Program on 
Reproductive Health and the Environment at the University of California, San Francisco 
(UCSF) Medical School.
The Promise of Stem Cells
Most of the work now under way in the United States and the European Union (EU) 
does not use human embryonic stem cells, which a 23 August 2010 ruling by the 
Federal District Court for the District of Columbia said cannot be supported by 
federal funds.
3 (On 9 September 2010, the U.S. Circuit Court of Appeals for the 
District of Columbia granted a request from the Justice Department that temporarily 
allows the government to resume funding research using human embryonic
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Using Stem Cells to Study  
Developmental Neurotoxicity
Growing
Knowledge
Neural stem cell culture
Fluorescent light micro-
graph of a cluster of human 
neural stem cells shows 
the cells differentiating 
into different cell types 
as they migrate out from 
the central neurosphere. 
Lighter blue indicates 
astroglial fibrillary acidic 
protein, yellow indicates 
neuronal tubulin III, and 
pink indicates nuclear DNA. Focus | Growing Knowledge   
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stem cells until the August decision is appealed.
4) 
Instead, most of the projects aimed at expand-
ing the ways to test for developmental neuro-
toxicity with human cells use neural stem cells—
or neuroprogenitor cells, as they are some-
times called—derived from human fetuses.
5 
Neuroprogenitor cells are considered to be 
multipotent because they can give rise to the 
three major cell types of the human brain. The 
cells can be derived from fetal nervous system 
tissue, human embryos, or adult nervous sys-
tem tissue, says Tim Shafer, a research toxicol-
ogist with the U.S. Environmental Protection 
Agency (EPA) Integrated Systems Toxicology 
Division.
Multipotent stem/progenitor cells are capa-
ble of generating some or all of the different 
types of cells required to maintain the health of 
one organ system. In contrast, pluripotent stem 
cells can produce the cells needed by more than 
one organ system. Embryonic stem cells are 
considered to be pluripotent. Only the zygote 
produced when a human sperm and egg merge 
and very early embryonic cells are truly toti-
potent in that they can generate any type of cell 
needed for human life including, importantly, 
the placenta and extraembryonic membranes 
(e.g., the amnion).6
The potential therapeutic applications of 
stem cells—such as for growing new skin for 
burn victims,7 aiding patients undergoing open-
heart surgery,8 or producing brain cells to treat 
people with Parkinson disease9—have already 
received a great deal of attention. However, 
stem cells’ anticipated value as research tools 
may be even greater, according to experts at a 
workshop on the topic held in June 2010 by the 
National Research Council (NRC) Standing 
Committee on the Use of Emerging Science for 
Environmental Health Decisions.10 
The ability of stem cells to differentiate into 
a wide variety of different cell types enables 
them to be used to model aspects of human 
biology that have been largely inaccessible to 
study by other means. In addition to prenatal 
developmental processes, this includes gene–
environment interactions and the production 
of cell types that are difficult to maintain in 
the laboratory, such as liver, kidney, and nerve 
cells. In the past, scientists who wanted to study 
human neuronal tissue used cells derived from 
nervous system tumors, which “may not be 
normal cells,” Shafer explains. The other alter-
native was to “use animals to make the culture 
every time you want cells.”  
Stem cells have the potential to improve 
how chemicals are evaluated because they 
involve using human cells, and they may be able 
to provide a broad range of data on a wide swath 
of chemicals much more quickly than conven-
tional toxicology testing, Woodruff points out. 
“It’s a noninvasive technique for humans to test 
effects on humans,” she says.
Stem cells have the added advantage of 
obviating the need for laboratory animals. 
“There has been a push to decrease the use 
of animal testing,” Woodruff says, noting 
that such a reduction is an explicit goal of the 
European Union’s Registration, Evaluation, 
Authorisation and Restriction of Chemical 
Substances regulatory framework. 
An NRC report released in 2007 pointed 
out that moving to in vitro methods, such as 
ones based on human stem cells, could greatly 
reduce the use of animals in testing, with the 
potential to eliminate animal testing altogether.11 
Using conventional animal-based neurotoxicity 
screening tests to evaluate the tens of thousands 
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Induced pluripotent 
stem cells derived from 
adult stem cells
Pluripotent
Umbilical cord blood 
stem cells
Totipotent 
Zygote Blastocyst Embryo
Multipotent 
Adult stem cells
Neural  
cells
Blood  
cells
Muscle 
cells
Bone 
cells
Liver 
cells
Stem cells: a potent force
Potency denotes a stem cell’s 
potential to differentiate into 
different cell types. Totipotent 
stem cells produced from the 
fusion of an egg and sperm cell 
can differentiate into any cell 
type including the placenta and 
extra  embryonic membranes. 
Pluripotent stem cells can dif-
ferentiate into nearly all cell types. 
Multipotent stem cells—undif-
ferentiated cells found in many 
tissues of the adult body—can 
differentiate into a number of cells 
within a single organ system.Focus | Growing Knowledge     
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of chemicals for which no neurotoxicity infor-
mation is available “is just plain impractical,” 
says Shafer, who is involved in a project using 
neuro  progenitor cells to evaluate how chemicals 
may be affecting human neurodevelopment. 
“The cost would be too great, it would take 
years and years to accomplish, and . . . it would 
take literally millions of animals.”
Using human stem cells in toxicology testing 
can overcome other detriments of animal test-
ing as well. Biologists have long suspected that 
because of differences between early embryonic 
development in rodents and humans, animal-
based testing may not always be a good pre-
dictor of human developmental neurotoxicity, 
particularly in the earliest stages. “It could be 
that for some particular pathways [such as the 
ones mediated by the aryl hydrocarbon receptor 
(AhR)], there are going to be these species differ-
ences,” Woodruff says. 
Differences between mouse cells and human 
cells “demonstrate that we do need to look 
at cells that are applicable to humans,” says 
Mary Alice Smith, an associate professor in the 
University of Georgia Environmental Health 
Science Department. “At this point, it looks as 
if there is a real difference between the human 
and the mouse cells for the AhR, and it may 
help explain some of the differences that we see 
between species.”
“Because signaling pathways do not develop 
simultaneously between species, toxicants can 
interfere in different ways,” explains Ellen 
Fritsche of the Environmental Health Research 
Institute in Düsseldorf and the University of 
Aachen. “Thus, animal experiments can over- or 
underestimate toxicities of chemicals—or give 
the right result. One must understand mecha-
nisms of biological processes in testing species 
and in comparison with humans as well as the 
mechanisms of chemical toxicities to be able 
to understand the predictive value of animal 
experiments.”
Finally, Woodruff says, human cells may 
help scientists assess the incremental risks associ-
ated with the levels of exposure experienced by 
the general public. Using human cells also gives 
researchers the opportunity to begin to try to 
account for the human genetic variability and 
susceptibility based on different life stages and 
disease status.
Research in 3-D
In Europe, teams in Germany and Poland are 
advancing the use of stem cells for develop-
mental neurotoxicity testing. The first and 
only validated test for assessing developmental 
neurotoxicity, based on rodent embryonic stem 
cells, was developed at the European Com-
mission’s European Center for the Validation 
of Alternative Methods.
12 Now this group is 
working on implementation of human embry-
onic stem cells for developmental neurotoxicity 
testing. The Johns Hopkins University’s 
Center for Alternatives to Animal Testing is 
working with groups in Europe and the United 
States to coordinate how the new technologies 
for evaluating developmental neurotoxicity are 
implemented.
Fritsche heads up one of the leading teams 
from Germany. Her group has been using 
neurospheres, a commercially available three-
dimensional (3-D) cell system created from 
human neuroprogenitor cells. Fritsche’s group 
has received funding from the German gov-
ernment to create neurosphere-based tests for 
assessing developmental neurotoxicity. The 
researchers have demonstrated that the cell 
systems can imitate some of the key processes 
of human neuronal development, including 
proliferation, differentiation, and migration.13 
Efforts by researchers in Poland and at the U.S. 
EPA to create tests to assess developmental 
neurotoxicity using stem or neuroprogenitor 
cells are looking at similar end points.
Experts agree these are some of the 
processes  critical  to  the  formation  of 
a functional nervous system.14 A carefully 
orchestrated symphony of enzymes, ion 
channels, and proteins all play important roles 
in the nervous system’s development, Shafer 
explains. In order for everything to develop 
properly, some processes must take place in 
a certain temporal sequence, whereas others 
are spatially dependent. If neurons cannot 
develop in the proper temporal and spatial 
sequence, or if the sequence is disrupted, 
the end result can be neurodevelopmental 
impairment, Shafer says.
The German researchers have demon  strated 
that exposing neurospheres to known neuro-
developmental toxicants including mercury 
chloride and methylmercury chloride decreases 
the number of nerve cells they produce and 
how far the cells migrate.13 Fritsche’s group 
also has used neurospheres to show exposure to 
polybrominated diphenyl ether (PBDE) flame 
retardants can alter human fetal brain cells by 
decreasing the distance that cells migrate by 
more than 25% during brain development.15 
Most recently, they compared the responses 
of human and mouse neurospheres to poly-
aromatic hydrocarbons, whose develop  mental 
neurotoxicity is based on activation of the 
AhR. Fritsche and colleagues found the AhR 
was not activated in the human test cells and 
wrote that “an accumulating body of evidence 
now indicates that human AhR signaling is less 
operative than AhR function in most labora-
tory animals.”16 
Neurospheres have the same weaknesses 
as other in vitro systems, Fritsche says: “No 
pharmacokinetics, as we do not have a whole 
organism, and limited metabolic capacity. The 
system is also limited to basic processes of brain 
development—no synaptic function, so far no 
network function, no higher cognitive func-
tions to evaluate.” 
But overall, neurospheres are very well 
suited for developmental neurotoxicity test-
ing, Fritsche says. Neurospheres are the “right 
species,” Fritsche says, and they represent the 
interplay between the different neural cell types 
(e.g., protection of neurons and glial cells) and 
can produce test results much more quickly and 
less expensively than animal-based tests. Where 
conventional testing takes about 18 months and 
requires approximately 140 female animals and 
1,000 offspring, the neurosphere assay takes 
four weeks (for assessing neuronal viability, 
proliferation, migration, differentiation, and 
apoptosis), Fritsche says. She estimates her 
group’s neurosphere-based tests cost approxi-
mately 80% less than conventional toxicology 
testing.
Fritsche contends the 3-D nature of the 
neurospheres also offers unique advantages. In 
unpublished work, she says she and her col-
leagues have shown that neurospheres express 
certain connexins, the molecules that form the 
gap junctions that mediate intercellular com-
munication. This communication is known to 
play an important role in maintaining tissue 
health and responding to changes in the cellular 
environment. However, she admits she hasn’t 
yet attempted to study how similar the intercel-
lular communication between neurospheres is 
to the way neurons communicate in the human 
body. She says she suspects “that at least some 
communication which exists in vivo is conserved 
after preparation of the cells.”
Another advantage of the neurospheres 
is that “cells are self-organized and influence 
each other by paracrine functions [which 
govern nearby cell signaling],” Fritsche says. 
“This makes the situation for the individual 
cell more ‘realistic’ than just a monolayer 
culture; [for example], some cells can protect 
neighboring cells.” 
This is demonstrated by comparing tests 
conducted with PBDEs using neurospheres 
and a human neuroblastoma cell line, she says. 
Although concentrations of BDE-47 greater 
than 5 µM have been shown to kill human 
neuroblastoma cells,
17 Fritsche says tests with 
human neurospheres showed no cytotoxicity at 
PBDE concentrations at least twice that high. 
However, the neurosphere tests did show that 
PBDEs had effects on migration and differen-
tiation into neurons and glial cells.
15 “We think 
it is important to investigate these end points 
as specific for developmental neurotoxicity in 
contrast to cytotoxicity, which is an unspecific 
measure,” Fritsche notes.
She and her colleagues have now evalu-
ated how neurospheres are affected by exposure 
to seven chemicals, including polychlorinated 
biphenyls, benzo[a]pyrene, 3-methylcholan-
threne, and 2,3,7,8-tetrachlorodibenzo-p-
dioxin.
16,18 They are currently assessing arsenic, 
the anticonvulsant valproic acid (which has been 
implicated in autism spectrum disorders
19) and methylazoxymethanol (which is known to affect 
neural functioning in animals
20) along with some 
other pesticides. To further validate the utility of 
neurospheres, the team also is testing them with 
compounds not expected to affect neural devel-
opmental, and their unpublished results suggest 
the assays can discriminate appropriately, she 
says. As a long-term vision, her group also plans 
to use progenitor cells from other organs to 
expand the kinds of toxicity testing they can do.
Cutting the Cord… 
and Putting It to Work
More than a decade ago, scientists from the 
Polish Academy of Sciences led by Krystyna 
Domanska-Janik were inspired to find another 
source of human stem cells besides embryonic 
tissue because their country’s government for-
bids its use. In time, they succeeded in devis-
ing an uncontroversial source of pluripotent-
like stem cells using human umbilical cord 
blood.
21 From there, team member Leonora 
Buzanska, who now heads the Stem Cell Bio-
engineering Laboratory at the academy’s Mos-
sakowski Medical Research Centre, found a 
way to generate a neural stem cell line.
22 
More recently, in collaboration with a 
research team led by Sandra Coecke of 
the European Commission Joint Research 
Centre’s In Vitro Models Unit, Buzanska and 
her Warsaw colleagues demonstrated this cell 
line can serve as the model system for devel-
opmental neurotoxicity testing.
23 The group 
confirmed the line’s response to chemicals 
known to be neurotoxic, including sodium 
tellurite, methylmercury chloride, cadmium 
chloride, chlorpyrifos, and l-glutamate. The 
group also showed that the cells were not 
affected by exposure to acetaminophen, theo-
phylline, or d-glutamate, and that their test 
system was able to identify differing suscepti-
bilities in different developmental stages. For 
example, the tests revealed that the less dif-
ferentiated cells were more sensitive to all of 
the known neurotoxicants except l-glutamate, 
which showed a higher toxicity to later stages. 
Buzanska is currently collaborating with a 
team of researchers led by François Rossi of the 
European Commission Joint Research Centre’s 
Nanobiosciences Unit to develop what she calls 
a “microplatform for stem cell growth and dif-
ferentiation with biofunctional microdomains.”
24 
The microdomains contain different “micro-
environments” that enable the stem cells to 
differentiate until they reach one of a number of 
points of development, Buzanska explains. 
The goal is to populate the platform with 
lineage-related stem cells that can be maintained 
at different developmental stages, beginning 
with the pluripotent stage and ending with 
functional neurons. The testing platform will 
enable scientists to simultaneously assess the 
influence of tested chemicals on different stages 
of neurodevelopment, as well as whether various 
microenvironments may play protective roles 
for the cells at defined stages, she says. Buzanska 
says her team is currently testing the microplat-
forms with methylmercury chloride. She hopes 
to publish her findings early in 2011.
Because processes of brain development 
are extremely complex, more than one in vitro 
model is needed to cover as many aspects as pos-
sible, Fritsche points out. “Buzanska’s cells could 
be a great addition to the proposed in vitro test-
ing battery,” she says. “It would be extremely 
helpful to generate such umbilical stem cell lines 
from individuals representing human genetic 
diversity. The great advantage is that availability 
of umbilical cord blood is unlimited.” 
What the Future Holds 
Both Buzanska and Fritsche believe their 
approaches to developmental neurotoxicity 
testing platforms will be speedier than conven-
tional animal testing, but whether Buzanska’s 
platform will ultimately be capable of high-
throughput testing is still an open question. 
Fritsche says neurospheres may not deliver 
more than what she calls “medium-throughput 
screening.” But not every compound has to 
be tested for developmental neurotoxicity, she 
points out; for instance, “the ones that don’t 
pass the placenta are not of interest [in this 
context].” The compounds that should be 
a priority for testing are endocrine disrup-
tors and those that show some potential for 
develop  mental toxicity based on animal screen-
ing, she says. Therefore, even though it takes 
four weeks to complete developmental neuro-
toxicity testing with neurospheres, they could 
easily be used to test around 100 compounds 
per year with an automated setup, she says.
Shafer’s project under way at the EPA is 
following an approach similar to the ones initi-
ated in Europe to use neuroprogenitor cells 
to evaluate how chemicals may affect human 
neuro  development. Shafer says his team’s 
goal is to develop what he calls a “first-tier” 
approach to identify chemicals that merit more 
detailed developmental neurotoxicity testing, 
perhaps following up with an alternative spe-
cies model such as zebrafish and then a rodent 
or other mammalian species.
The neurodevelopmental processes for which 
Shafer and his colleagues are devising assays 
include proliferation, differentiation, neurite 
growth, the creation of synapse gaps (synapto-
genesis), migration, myelination, and apoptosis. 
As the group works to develop assays to test how 
chemicals affect these processes, one objective 
is to ensure the assays are amenable to high-
throughput testing, Shafer says. They are using 
monolayers of the commercial ReNcell CX 
model, derived from a human fetus. This will 
enable others to easily conduct the same tests, he 
says, and the two-dimensional mono  layers also 
are more amenable to high-throughput testing 
than the 3-D neurospheres.
Of the neurotoxicity suite that Shafer’s 
group is developing, the proliferation assay is one 
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Using Stem Cells to Investigate Autism
Ricardo Dolmetsch, a neurobiologist at Stanford University, is employing a very different approach 
to using stem cells in research related to children’s environmental health. Dolmetsch’s group is 
using human stem cells to investigate autism spectrum disorders (ASDs), and his group is laying the 
groundwork that may eventually allow them to create a system for screening environmental agents 
to assess whether they could play a role in these disorders, he says.
The reported incidence of ASDs has been rising, and although some circumstantial evidence 
points to environmental agents, good data are sorely lacking, Dolmetsch says. Tracking down links 
with conventional animal models is problematic because scientists believe some important classes 
of neurons exist only in primates, he points out.
Dolmetsch has succeeded in identifying some of the genes involved in ASDs by focusing on 
relatively rare disorders known to have a genetic link. Such groups of patients are likely to have 
similar “cellular molecular signatures,” he explains.
He and his colleagues harvest cells from these patients’ skin and reprogram them to become 
induced pluripotent stem cells, which are then converted into functional cells. The research team 
has successfully produced a wide variety of neurons and glial cells, including catecholaminergic 
cells, which control the secretion of hormones such as dopamine that have been implicated in both 
schizophrenia and autism.
In unpublished work presented at the NRC meeting in June,10 Dolmetsch’s group reported success 
at identifying genes associated with the calcium signaling deficits and cardiac irregularities found 
in patients with Timothy syndrome, a rare disease characterized by webbed fingers and toes that 
is often associated with developmental delays and autism. They have also discovered a compound 
that appears to reverse the calcium signaling issues, which Dolmetsch says may ultimately help 
pharmacologists discover a drug that would help children with the syndrome.
The Stanford group is investigating links their work has turned up with other rare ASDs, too. 
They credit their successes thus far to what Dolmetsch calls the focused approach of narrowing in 
on genes they suspect to be involved with the diseases they are studying. Although Dolmetsch’s 
group has not yet used induced pluripotent stem cells to study environmental triggers of ASDs, he 
says he believes “that at least in principle it is doable.” Focus | Growing Knowledge
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of the furthest along. Neuroprogenitor prolifera-
tion is crucial to early brain development, when 
the neural tube expands rapidly and its ante-
rior portion eventually gives rise to the brain. 
The proliferation assay initially proved itself in 
a small test with a group of chemicals docu-
mented to affect proliferation.
25 More recently, 
the researchers tested the assay’s performance 
with the 309 biologically active chemicals being 
evaluated by the ToxCast™ program run by the 
EPA National Center for Computational Toxi-
cology. The Shafer group’s assay showed that 
125 ToxCast chemicals had a significant impact 
on neural proliferation.
26 (Further unpublished 
work put that number at 112.) Participation 
in the program will allow these results to be 
compared with those from other screening and 
testing efforts, Shafer says.
At press time it was unclear how the ulti-
mate fate of the August ruling on stem cells 
would affect projects of some of the researchers 
interviewed for this article. For instance, Smith 
is collaborating with Steve Stice, director of the 
University of Georgia Regenerative Bioscience 
Center, to develop a way to use “germ-like” cells 
derived from human embryonic stem cells to 
produce an in vitro system for investigating the 
developmental and reproductive effects of com-
pounds that affect endocrine-system functioning. 
Early in human development, Smith explains, 
cells that eventually become part of the male or 
female reproductive system express two proteins, 
DDX4 and POU5f1. Smith and Stice had been 
measuring changes in metabolite levels in cells 
that express these proteins to determine the bio-
chemical consequences of exposure to environ-
mental chemicals. Smith says in time they also 
would like to look at impacts on neuronal cells.
In other human embryonic stem cell work, 
Woodruff and Mike McMaster of the UCSF 
departments of Cell and Tissue Biology and 
Obstetrics, Gynecology, and Reproductive Sci-
ences are exposing stem cells to bisphenol A 
at levels similar to those measured in pregnant 
women and their fetuses. The team will examine 
how these exposures affect the cells’ gene expres-
sion profiles and developmental potential.
One possible alternative to human embry-
onic stem cells that was discussed at the June 
NRC meeting is what are known as induced 
pluripotent stem cells. In the past few years, 
scientists have begun to recognize that the 
somatic cells that compose the vast majority of 
the adult human body can be “reprogrammed” 
to create these induced pluripotent stem cells, 
says M. William Lensch of Harvard Univer-
sity’s Children’s Hospital and the Harvard 
Stem Cell Institute. This is possible because 
all of an individual’s cells contain the same 
DNA required to produce the entire body, he 
explains. An individual’s functional cells, such 
as skin cells and liver cells, differ from one 
another because they express different parts 
of the DNA. The reprogramming process 
involves the cells’ chromatin, which controls 
which genes are expressed.
Induced pluripotent stem cells are being 
used to produce a variety of human cell types, 
and researchers believe that, like embryonic 
stem cells, they can give rise to all of the body’s 
cell types. In the future, human induced pluri-
potent cells may prove useful for developmental 
neurotoxicity testing, Shafer says. They have the 
potential to help researchers represent a greater 
degree of genetic variability, he says.
The Regulatory Imperative
Until recently, most of what was known about 
developmental neurotoxicity was the result 
of tragic accidents with lead, methylmercury, 
polychlorinated biphenyls (PCBs), arsenic, 
and toluene.
2 In the past few years, prospective 
birth cohort epidemiologic studies undertaken 
in the NIEHS-funded Centers for Children’s 
Environmental Health and Disease Prevention 
Research have taught us more, indicating that 
arsenic, manganese, organochlorine pesticides, 
polybrominated diphenyl ethers, phthalates, 
and bisphenol A also are likely to adversely 
affect infant brain development.
2
Philip Landrigan of the Mount Sinai School 
of Medicine points out that of the approximately 
3,000 chemicals used in quantities of more than 
1 million pounds per year in the United States, 
only a small fraction have been tested at all to 
assess whether they can cause damage to the 
developing brain and nervous system. “Eighty 
percent of the chemicals to which children are 
exposed every day from conception on are chem-
icals whose possible toxic effects on the brain and 
nervous system are simply unknown,” he says.
But neurobehavioral damage caused by 
environmental chemicals is preventable, and 
in an influential 2006 paper, Landrigan and 
Philippe Grandjean of the Harvard School 
of Public Health argued that “testing of new 
chemicals before allowing them to be marketed 
is a highly efficient means to prevent toxicity.”
2 
At the end of the day, Shafer says, “anything 
that can be done to increase the number of 
chemicals that we can collect toxicological 
information on is an improvement [over the 
current state of affairs].”  
However, having good tests in place to con-
duct accurate hazard assessments of the chemi-
cals in use today is only part of the solution. 
Without a legislative or regulatory mandate to 
conduct such testing, public health experts like 
Landrigan question whether it will be done. He 
says he blames the chemical industry for not 
taking responsibility for the products they make 
and sell, and he faults the government for not 
enforcing the law. 
“I’m very frustrated that the testing has 
just not been done for so many of these chemi-
cals. I think the failure to test chemicals under 
[TSCA] represents a grave lapse in steward-
ship,” Landrigan charges. Bills that would 
revamp TSCA and require more chemical test-
ing have been introduced in both houses of 
the U.S. Congress.
27,28 Additionally, the EPA 
has proposed several rules intended to improve 
chemical reporting under TSCA.
29
Meanwhile, people today, and especially chil-
dren, are exposed to thousands of chemicals that 
have never been properly tested for toxicity—or 
tested at all, Landrigan says. “It is a very worri-
some prospect,” he says, “to consider that chemi-
cals that children are exposed to every day that 
are widely detected in the blood of pregnant 
women, in breast milk, and in cord blood could 
well be neurotoxic chemicals whose neurotoxicity 
has just never been properly examined.” 
Kellyn S. Betts has written about environmental contami-
nants, hazards, and technology for solving environmental 
problems for publications including EHP and Environmental 
Science & Technology for more than a dozen years.
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